NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Primary objective:
- To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine
ratio (ACR) in patients with type 2 diabetes and albuminuria
Secondary objectives:
- To characterize the effect of study drug on glycosylated hemoglobin fraction (HbA1c)
- To evaluate the effect of study drug on markers of glycemic disorders, systemic
inflammation, renal and liver disease and cardiovascular function
- To assess the safety and tolerability of study drug
- To determine the population pharmacokinetics (PK) of study drug